(secondQuint)Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients.

 BCD-017-3 is an double-blind randomized phase III clinical study to compare the incidence of CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated filgrastim empegfilgrastim (Extimia(R)) at a dose of 6 or 7.

5 mg versus daily administration of filgrastim at a dose of 5 1/2g/kg/day for neutropenia prophylaxis in breast cancer patients receiving myelosuppressive chemotherapy.

 The study also includes the following determination of pharmacokinetic parameters after repeated administration of the study drug.

.

 Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients@highlight

The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2).

